HSBC Holdings’s Black Diamond Therapeutics BDTX Stock Holding History

HSBC Holdings’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.4K	Hold	26,421	–	–	﹤0.01%	2863
2026 Q1	$56.8K	Hold	26,421	–	–	﹤0.01%	2796
2025 Q4	$66.8K	Hold	26,421	–	–	﹤0.01%	2837
2025 Q3	$97.8K	Sell	26,421 -15,278	-37%	-$44.7K	﹤0.01%	2599
2025 Q2	$99.5K	Buy	41,699 +14,570	+54%	+$28.1K	﹤0.01%	2855
2025 Q1	$42.3K	Sell	27,129 -30	-0.1%	-$63	﹤0.01%	2923
2024 Q4	$59.2K	Buy	27,159 +13,511	+99%	+$38.7K	﹤0.01%	2966
2024 Q3	$57.3K	Buy	+13,648	New	+$74.3K	﹤0.01%	2870
2023 Q3	–	Sell	-24,156	Closed	-$120K	–	2717
2023 Q2	$120K	Hold	24,156	–	–	﹤0.01%	2405
2023 Q1	$44.9K	Hold	24,156	–	–	﹤0.01%	2572
2022 Q4	$43.2K	Buy	24,156 +11	+0%	+$20	﹤0.01%	2976
2022 Q3	$41K	Sell	24,145 -1,891	-7%	-$5.83K	﹤0.01%	2835
2022 Q2	$64K	Hold	26,036	–	–	﹤0.01%	3107
2022 Q1	$72K	Hold	26,036	–	–	﹤0.01%	3168
2021 Q4	$143K	Buy	+26,036	New	+$182K	﹤0.01%	3098
2021 Q1	–	Sell	-8,518	Closed	-$274K	–	2740
2020 Q4	$274K	Buy	+8,518	New	+$280K	﹤0.01%	2623

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

HSBC Holdings's BDTX Position: Q2 2026 in Review

HSBC Holdings held its Black Diamond Therapeutics (BDTX) position steady in Q2 2026 at 26,421 shares worth $46.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2863.

HSBC Holdings first reported a position in BDTX in Q4 2020 and has held it in 16 quarters since. The position peaked at $274K in Q4 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

HSBC Holdings held 26,421 shares of Black Diamond Therapeutics worth $46.4K as of Q2 2026.
HSBC Holdings left its Black Diamond Therapeutics share count unchanged in Q2 2026.
Black Diamond Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2863 holding.
HSBC Holdings first reported a position in Black Diamond Therapeutics in Q4 2020 and has held it in 16 quarters since.
HSBC Holdings's Black Diamond Therapeutics position peaked at $274K in Q4 2020.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.